Epicore BioNetworks Inc. Announces New Board Director

    CALGARY, March 20 /CNW/ - The Board of Directors of Epicore BioNetworks
Inc. is pleased to announce a new director has joined the board, effective
March 19, 2007. The Board welcomes Mr. Fred N. Boulos of Beaconsfield, Quebec,
    Mr. Boulos has over thirty three years business experience in operations
management of Canadian and international companies. His experience includes
engineering and construction of oil exploration and pipeline systems and many
other interesting projects. He has had contract management and procurement
responsibility for multi-million dollar projects. Much of his work experience
is in the Middle East and Africa region, which is growing in importance to
aquaculture suppliers. Mr. Boulos holds degrees in engineering, marketing and
investment analysis. The Board expects that his knowledge and experience will
be of great benefit to Epicore.
    The Board of Directors has approved issuance to Mr. Boulos of 150,000
options to buy Epicore common shares, pursuant to the terms of the Company's
stock option program. The shares will be priced at Cdn $0.125 per share.

    Epicore BioNetworks Inc. is a leading producer of environmental
biotechnology and animal nutrition products. It manufactures in the USA and
markets worldwide to a variety of industries to reduce environmental pollution
and increase operational productivity.
    Epicore BioNetworks Inc. is a public corporation with a registered office
in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange
(symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.)

    This press release contains forward-looking statements that involve
significant risks and uncertainties. The actual results, performance or
achievements of the Company might differ materially from the results,
performance or achievements of the Company expressed or implied by such
forward-looking statements. Such forward-looking statements include, without
limitation, those regarding the development plans of the Company and the
expected timing and results of such development. We can provide no assurance
that such development will proceed as currently anticipated or that the
expected timing or results of such development will be realized. We are
subject to various risks, including the uncertainties of product development,
markets for our products and regulatory review, our need for additional
capital to fund our operations, our reliance on collaborative partners, our
history of losses, and other risks inherent in the biotechnology industry.

For further information:

For further information: Mr. William P. Long (Chief Executive Officer),
Tel: (609) 267-9118

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890